Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.
Verastem, Inc.
Servier
Eli Lilly and Company
Tango Therapeutics, Inc.
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Turning Point Therapeutics, Inc.
Obsidian Therapeutics, Inc.
Novartis
Frontier Medicines Corporation
Bristol-Myers Squibb
Filamon LTD
PMV Pharmaceuticals, Inc
Revolution Medicines, Inc.
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A2 Biotherapeutics Inc.
Avenzo Therapeutics, Inc.
Revolution Medicines, Inc.
Incyte Corporation
Auricula Biosciences Inc.
Xemed LLC
3H Pharmaceuticals Co., Ltd.
Second Life Therapeutics
Exelixis
Pfizer
Eli Lilly and Company
Inhibrx Biosciences, Inc
SignalChem Lifesciences Corporation
Beijing Pearl Biotechnology Limited Liability Company
VM Oncology, LLC
Black Diamond Therapeutics, Inc.
Takeda
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
NantCell, Inc.
Tango Therapeutics, Inc.
Shasqi, Inc.
Revolution Medicines, Inc.
Krystal Biotech, Inc.
Daiichi Sankyo
LigaChem Biosciences, Inc.
Phanes Therapeutics
Shanghai Escugen Biotechnology Co., Ltd
A2 Biotherapeutics Inc.
Incyte Corporation
Navigation Sciences, Inc.
Marengo Therapeutics, Inc.
Hoffmann-La Roche
Avistone Biotechnology Co., Ltd.
Verastem, Inc.